Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Accumulated Depreciation (2021 - 2025)

Stoke Therapeutics has reported Accumulated Depreciation over the past 5 years, most recently at $10.1 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation rose 14.67% year-over-year to $10.1 million; the TTM value through Dec 2025 reached $10.1 million, up 14.67%, while the annual FY2025 figure was $10.1 million, 14.67% up from the prior year.
  • Accumulated Depreciation for Q4 2025 was $10.1 million at Stoke Therapeutics, up from $8.8 million in the prior quarter.
  • Over five years, Accumulated Depreciation peaked at $10.1 million in Q4 2025 and troughed at $2.7 million in Q4 2021.
  • A 5-year average of $6.5 million and a median of $6.7 million in 2023 define the central range for Accumulated Depreciation.
  • Biggest five-year swings in Accumulated Depreciation: soared 58.57% in 2023 and later increased 14.67% in 2025.
  • Year by year, Accumulated Depreciation stood at $2.7 million in 2021, then surged by 58.1% to $4.2 million in 2022, then soared by 58.57% to $6.7 million in 2023, then skyrocketed by 32.63% to $8.8 million in 2024, then increased by 14.67% to $10.1 million in 2025.
  • Business Quant data shows Accumulated Depreciation for STOK at $10.1 million in Q4 2025, $8.8 million in Q4 2024, and $6.7 million in Q4 2023.